Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Jong Soo Woo

Jae Hyun Park

Yong Il Kim

Kyeong Soo Kim

Ho Taek Im

Jin Cheul Kim

Taek Kwan Kwon

Dong Ho Kim

Yo Han Kim

Deokkyu Lee

Ho Taek Yim

Young Su Yoon

Min Jung Kim

Yong-Il Kim

Gwan Sun Lee

Chang Hyun Lee

Jung Hyun Cho

Young Il Kim

Young Hun Kim

Young Kil Chang

Jun Young Choi

Young Ho Moon

Seung Jae Park

Nam Du Kim

Young Keun Choi

Sang Wook Kim

Moon-Hyuk Chi

Ji Hyun Im

Hong-Gi Yi

Myeong Ki Jung

Si-Young Jung

Hong Gi Yi

Yun Ah Lee

Seung Hun Chang

Si Young Jung

Shanmugam Srinivasan

Ae Guk Kim

Seung Jun Lee

Myoung Ki Jeong

Hyuk Jun Cho

Caleb Hyung Min Park

Yong Ii Kim

Jae-Kuk Ryu

Leedong Roh

Ki Young Jang

Young Jun Na

Kwang Young Lee

Teak Kwan Kwon

Hyung Seo Kim

Young-Hun Kim

Mijin Park

Hee Chul Chang

Eun Jin Yoon

Yoon Sub Shin

Moon Hyuk Chi

Young Ho Hwanggolmaeul Jugong Apt Moon

Kyung Ik Lee

Jae Kuk Ryu

Caleb Hyung Park

Young-Su Yoon

Caleb Hyungmin Park

Jae Ho Kim

Benjamin Joon Lee

Jin Wook Tak

An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent.

Oral solid formulation containing irinotecan and method of preparing the same

Provided are a composite capsule and a method of preparing the composite capsule. The composite capsule includes a first dissolving part including a core, an inner coating layer on the core, and a first enteric coating layer on the inner coating layer, wherein core contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof. The composite capsule further includes a second dissolving part including a core, which contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof, an inner coating layer on the core, and a second enteric coating layer on the inner coating layer.

Esomeprazole-containing complex capsule and preparation method therefor

Disclosed is a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation, based on considerably improved pH-dependent drug release characteristics, starts to release the esomeprazole or a pharmaceutically acceptable salt thereof at a target delay time after oral administration, continues the release for a predetermined time, and finishes the release after a predetermined time, thereby providing excellent patient convenience and excellent therapeutic effects, as compared to conventional other formulations.

Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof

Provided are a solid composite formulation for oral administration, the solid composite formulation including: an ezetimibe granules-part including ezetimibe, said ezetimibe having a particle size distribution wherein the average particle size d(0.9) for the bottom 90% is about 10 &#x3bc;m or less; and a rosuvastatin mixture-part including rosuvastatin or a pharmaceutically acceptable salt thereof, and a method of preparing the composite formulation.

Composite formulation for oral administration comprising ezetimibe and rosuvastatin

The present invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disorders containing losartan or a pharmaceutically acceptable salt thereof; amlodipine or a pharmaceutically acceptable salt thereof; a disintegrant; and a coating agent. The composition of the present invention, which has the best combination and optimum ratio of a disintegrant to a coating agent, shows sufficient strength and high dissolution rates under various pH environments, and thus, it is useful for the preparation of an excellent solid formulation exhibiting improved drug delivery efficiency and storage stability.

Solid pharmaceutical composition comprising amlodipine and losartan

Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time.

Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant

Provided is an amorphous solid dispersion including a taxane or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymer, and a pharmaceutically acceptable surfactant, which has enhanced solubility. Also provided is a method for preparing the solid dispersion. The present subject matter also provides a tablet having good solubility, bioavailability and stability, which comprises the amorphous solid dispersion, an intragranular excipient, and an extragranular excipient.

Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same

Disclosed is a pharmaceutical combination formulation comprising a first discrete part containing amlodipine and rosuvastatin and a second discrete part containing losartan, which exhibits improved dissolution rate and stability. The inventive combination formulation comprising amlodipine, losartan and rosuvastatin having different action mechanisms from one another can be effectively used to prevent or treat a cardiovascular disorder. Designed to minimize an interaction among active ingredients, the pharmaceutical combination formulation exhibits excellent storage stability and dissolution rates of amlodipine, losartan and rosuvastatin, and thus can be useful in pharmaceutical industries.

Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin

The present invention relates to a complex granule formulation comprising a first granular part comprising levocetirizine or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent; and a second granular part comprising montelukast or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent. This formulation can effectively inhibit the production of related compounds of levocetirizine and montelukast by allowing levocetirizine and montelukast to form clathrate complexes with cyclodextrin, and using an alkalinizing agent. This formulation not only shows increased stability and bioavailability, but also improves patient compliance owing to its effective masking of bitter taste.

Complex granule formulation having improved stability comprising levocetirizine and montelukast

An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.

Oral complex composition comprising pseudoephedrine and levocetirizine

Disclosed are a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same and a method for preparing the same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.

Method for preparing dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide

The present invention relates to a pharmaceutical formulation for oral administration for preventing or treating allergic rhinitis or asthma, which comprises: (a) a first particle part comprising levocetirizine or a pharmaceutically acceptable salt thereof and an organic acid; and (b) a second particle part comprising montelukast or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention comprises an organic acid as a stabilizing agent, which can effectively inhibit the production of levocetirizine and montelukast related substances, and thus, show good stability.

Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof

Provided is a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.

Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same

The present invention relates to an amorphous solid dispersion comprising a tetrazole derivative of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The solid dispersion of the present invention comprises a water-soluble polymer or an acid so as to improve the solubility of its active ingredient, i.e., the tetrazole derivative of the formula (I), thereby improving its absorption rate, and thus can be effectively used to reduce multi-drug resistance (MDR) in cancer cells.

Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient

Growing community of inventors

Suwon-si, South Korea

Jong Soo Woo